Luminary Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 9

Luminary Therapeutics General Information

Description

Developer of a cell therapy platform designed for the treatment of cancer and autoimmune diseases. The company's platform develops allogeneic gamma delta T-cell-based chimeric antigen receptor (CAR) and T-cell receptor (TCR) therapies using a proprietary manufacturing platform for hematologic malignancies, solid tumors, and autoimmune disorders, enabling healthcare providers to access off-the-shelf cell therapies.

Contact Information

Website
www.luminarytx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1200 Washington Avenue South
  • Suite 260
  • Minneapolis, MN 55415
  • United States
+1 (612)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 1200 Washington Avenue South
  • Suite 260
  • Minneapolis, MN 55415
  • United States
+1 (612)

Luminary Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Luminary Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Accelerator/Incubator 06-Nov-2025 Completed Generating Revenue
10. Later Stage VC 14-Oct-2025 Completed Generating Revenue
9. Later Stage VC (Series B) 14-Apr-2025 Completed Generating Revenue
8. Secondary Transaction - Private Completed Clinical Trials - Phase 1
7. Later Stage VC (Series A1) 27-Jan-2025 Completed Clinical Trials - Phase 1
6. Grant 29-Oct-2024 Completed Clinical Trials - Phase 1
5. Accelerator/Incubator 14-Oct-2023 Completed Startup
4. Early Stage VC (Series A) 04-Nov-2021 Completed Pre-Clinical Trials
3. Grant 01-Aug-2021 $400K $1.49M Completed Pre-Clinical Trials
2. Grant 08-Sep-2020 $397K $1.49M Completed Pre-Clinical Trials
To view Luminary Therapeutics’s complete valuation and funding history, request access »

Luminary Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B-2
Series B-1
Series A-1A
Series A-1 220,486 $0.000100 8% $3.61 $3.61 1x $3.61 3.36%
Series A 1,822,500 $0.000100 8% $2 $2 1x $2 27.8%
To view Luminary Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Luminary Therapeutics Patents

  • 2

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 2

    Pending

  • Expiring in next 12 mo

Luminary Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026136393-A1 Dual-action antigen-presenting gamma delta car t-cells Pending 17-Dec-2024
WO-2025199494-A1 Methods of generating populations of therapeutic cells Pending 22-Mar-2024

Luminary Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Luminary Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cure Experience Services Accelerator/Incubator
NuFund Venture Group Angel Group Minority
Lunch Pail Ventures Angel Group Minority
701 Fund Angel Group Minority
Gopher Angels Angel Group Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Luminary Therapeutics FAQs

  • When was Luminary Therapeutics founded?

    Luminary Therapeutics was founded in 2019.

  • Where is Luminary Therapeutics headquartered?

    Luminary Therapeutics is headquartered in Minneapolis, MN.

  • What is the size of Luminary Therapeutics?

    Luminary Therapeutics has 8 total employees.

  • What industry is Luminary Therapeutics in?

    Luminary Therapeutics’s primary industry is Drug Discovery.

  • Is Luminary Therapeutics a private or public company?

    Luminary Therapeutics is a Private company.

  • What is Luminary Therapeutics’s current revenue?

    The current revenue for Luminary Therapeutics is .

  • How much funding has Luminary Therapeutics raised over time?

    Luminary Therapeutics has raised $24.2M.

  • Who are Luminary Therapeutics’s investors?

    Cure Experience Services, NuFund Venture Group, Lunch Pail Ventures, 701 Fund, and Gopher Angels are 5 of 9 investors who have invested in Luminary Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process